Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Clocks in Translational Roadmap for Circadian-Based Therapeutics in Lung Diseases.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

scRNA sequencing revealed HIV-associated inflammation-mediated lung epithelial dysregulation and fibroblast remodeling.

Frontiers in immunology·2026
Same author

SenSet defines cell-type specific senescence signatures in the aged human lung.

The EMBO journal·2026
Same author

Toxicity, Chemistry, and Public Health Relevance of Emerging Nicotine Analog Vapes, Pods, and Pouches.

Chemical research in toxicology·2026
Same author

PPAR-gamma regulates PFAS-mediated proinflammatory cytokines in lung epithelial cells.

Frontiers in pharmacology·2026
Same author

A comparative toxicological evaluation of nicotine and its analog 6-methyl nicotine in E-cigarette aerosol utilizing a 3D in vitro human respiratory model.

Toxicology·2026

Related Experiment Video

Updated: Jun 26, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

Antioxidant therapeutic advances in COPD.

Irfan Rahman1

  • 1Department of Environmental Medicine, Lung Biology and Disease Program, University of Rochester Medical Center, Rochester, NY, USA. irfan_rahman@urmc.rochester.edu

Therapeutic Advances in Respiratory Disease
|January 7, 2009
PubMed
Summary

Targeting oxidative stress with antioxidants may benefit chronic obstructive pulmonary disease (COPD) treatment. Enhancing lung antioxidant levels, including thiol antioxidants and Nrf2 activators, shows promise for managing COPD progression and inflammation.

Related Experiment Videos

Last Updated: Jun 26, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

Area of Science:

  • Pulmonary Medicine
  • Oxidative Stress Research
  • Pharmacology

Background:

  • Chronic obstructive pulmonary disease (COPD) significantly contributes to morbidity and mortality.
  • Oxidative stress from cigarette smoke is a key factor in COPD progression and exacerbation.

Purpose of the Study:

  • To review strategies for enhancing lung antioxidant levels in COPD.
  • To examine advances in antioxidant therapies and recent clinical trials for COPD management.

Main Methods:

  • Review of existing literature on antioxidants and mucolytics for COPD.
  • Analysis of various antioxidant compounds including thiol antioxidants, Nrf2 activators, and polyphenols.
  • Examination of specific spin traps and catalytic antioxidants investigated for COPD.

Main Results:

  • Thiol antioxidants, Nrf2 activators, and dietary polyphenols increase intracellular thiol status and GSH biosynthesis, aiding free radical detoxification and reducing inflammation.
  • Specific agents like spin traps and SOD mimetics have shown efficacy in inhibiting cigarette smoke-induced lung inflammation.
  • Multiple antioxidants and mucolytics may be effective, but therapy choice must align with specific COPD phenotypes.

Conclusions:

  • Enhancing endogenous antioxidant levels and utilizing targeted antioxidant therapies hold potential for COPD treatment.
  • Understanding COPD pathophysiology is crucial for selecting effective antioxidant strategies.
  • Further clinical trials are needed to validate the efficacy of various antioxidant compounds in managing COPD.